RESUMO
Epidermal growth factor receptor 2 (HER2) is an oncogene involved in tumour genesis and progression. It is expressed in 7% of patients with colorectal cancer (CRC) and is associated with drug resistance of epidermal growth factor receptor monoclonal antibodies. With the emergence of the therapeutic dilemma of CRC and the survival benefits of targeting HER2 for patients with breast cancer and gastric cancer, the significance of HER2 in CRC and the prognostic value of anti-HER2 therapy have been widely concerned, clinical researches on HER2-positive CRC have been continuously carried out. Currently, the diagnostic criteria for HER2 positive CRC have gradually been unified. HER2-targeting therapies such as monoclonal antibodies, tyrosine kinase inhibitors, antibody-drug coupling and HER2-related immunotherapy alone or in combination have shown good efficacy and brought significant survival benefits for HER2 positive CRC. This paper reviews the research progress of HER2 in CRC.
RESUMO
BACKGROUND: Malignant mesotheliomas are histologically heterogeneous neoplasms. Definite diagnosis requires a varied panel of immunohistochemical (IHC) markers to differentiate these from histological mimics. Only a few case series have been reported in the Indian literature where mesotheliomas have been analyzed on routine histology and IHC. AIM: To evaluate the histological features of malignant mesothelioma and to elucidate the best possible immunomarker combination useful in different scenarios. MATERIALS AND METHODS: A total of 24 cases of malignant mesotheliomas of different sites encountered over a 6-year period were retrospectively analyzed with regard to their histomorphology and IHC findings. RESULTS: The pleura was the most common site of involvement (16 cases) followed by peritoneum (5 cases) and pericardium (3 cases). Epithelioid mesothelioma was the most common histological type (15 cases, 62.5%) followed by sarcomatoid (5 cases, 20.84%), deciduoid (2 cases, 8.34%), and 1 case each of desmoplastic and biphasic mesothelioma. Among the mesothelial markers, WT1 was positive in 17 of 20 (85%) cases and calretinin was positive in 20 of 21 (95.23%) cases. D2-40 and CK5/6 were positive in all cases where they were studied. Adenocarcinoma markers TTF-1, napsin A, and CEA had very high negative predictive value in ruling out mesothelioma. CONCLUSION: The differential diagnosis of mesotheliomas varies with histological type and tumor location. Judicious use of various combinations of IHC markers in different situation has been highlighted in this article
RESUMO
Objective:To observe the effect of thoracic infusion of pseudomonas aeruginosa injection in malignant pleural effusion. Methods:A total of 90 patients with malignant pleural effusion were randomly divided into treatment group (31 cases),control group A (29 cases) and control group B(30 cases). Treatment group was treated with pseudomonas aeruginosa through intrathoracic infusion. Control group A and B were respectively treated with cisplatin and interleukin-2 through intrathoracic infusion. The clinical efficacy and adverse reaction were compared among the three groups. Results:The total effective rate of treatment group was 80.6%,the total effective rates of the control group A and B were 51.7%and 56.7%respectively.Compared with that of contral groups, the total effective rate of treatment group was higher, and the differences were statistically significant (P<0.05). The incidence of serious side effects and toxicity was lower in treatment group than in control groups. Conclusion:The effect of thoracic infusion of pseudomonas aeruginosa injection for malignant pleural effusion is significant, and the adverse reaction is mild. Thus it is worth to be promoted clinically.